Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Repare Therapeutics Inc.

< Previous 1 2 Next >
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Regain Global Rights to Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.